A Phase I/II Study to Investigate the Safety, Tolerability and Potential Activity of IPI-504 in Relapsed and / or Refractory Stage IIIb (With Malignant Pleural or Pericardial Effusion), or Stage IV NSCLC [non-small cell lung cancer] Patients.

Trial Profile

A Phase I/II Study to Investigate the Safety, Tolerability and Potential Activity of IPI-504 in Relapsed and / or Refractory Stage IIIb (With Malignant Pleural or Pericardial Effusion), or Stage IV NSCLC [non-small cell lung cancer] Patients.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2012

At a glance

  • Drugs Retaspimycin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 05 Mar 2012 Actual patient number changed from 76 to 88 as reported by ClinicalTrials.gov.
    • 05 Mar 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 05 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top